US-based therapeutic developer for muscular dystrophy PTC Therapeutics establishes corporation in Tokyo

Mar 27, 2017

PTC Therapeutics Inc., a US company engaged in development, manufacturing and sales of a drug for muscular dystrophy (MD), established PTC Therapeutics Japan in August, 2015. Muscular dystrophy is a genetic disorder that causes necrosis of skeletal muscles. Designating it a difficult-to-treat disease, the Japanese government provides support for the development of therapeutic drugs for the disease. PTC Therapeutics's drug for MD has obtained marketing certification in Europe and it is already in the process of marketing certification procedures in Japan.

For the establishment of PTC Therapeutics' subsidiary in Japan, the JETRO Invest Japan Business Support Center (IBSC) provided information on approval and the certification system related to pharmaceuticals in Japan.